{"schema_version":"secwatch.filing_event.v1","accession":"0000917520-24-000017","form_type":"8-K","ticker":"IART","cik":"0000917520","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.283502+00:00","generated_at":"2026-06-05T10:14:57.793273+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Integra LifeSciences Q4 GAAP EPS $0.25 vs $0.63; guides FY2024 revenue up 4-5% organic","bullets":["Q4 revenues $397.0M, down 0.2% reported; organic revenue ex-Boston up 3.6%.","GAAP EPS $0.25, adjusted EPS $0.89 vs $0.94 prior year.","Full-year 2023 adjusted EPS $3.10 vs $3.36; Boston relaunch on track for mid-to-late Q2 2024.","Signed definitive agreement to acquire Acclarent ENT business expected to close by Q2 2024.","FY2024 guidance: revenue $1,603M-$1,618M (organic +4-5%), adjusted EPS $3.15-$3.25."],"urls":{"canonical":"https://secwatch.observer/filing/0000917520-24-000017","json":"https://secwatch.observer/filing/0000917520-24-000017.json","markdown":"https://secwatch.observer/filing/0000917520-24-000017.md","text":"https://secwatch.observer/filing/0000917520-24-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/917520/000091752024000017/0000917520-24-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/917520/000091752024000017/iart-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T10:14:57.793273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2dd85b4055528b5dd758c3d8a9f12d9a7d947c5","claim":"INTEGRA LIFESCIENCES HOLDINGS CORP reported full-year 2024 results: revenue $1,603 million to $1,618 million, EPS $3.15 to $3.25. Guidance initiated.","evidence_excerpt":"For the full-year 2024, the Company expects revenues to be in a range of $1,603 million to $1,618 million, representing reported growth of approximately 4.0% to 5.0% and organic growth in the range of 4.0% to 5.0%. Adjusted earnings per diluted share are expected to be between $3.15 and $3.25.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752024000017/0000917520-24-000017-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2024"},{"label":"Revenue","value":"$1,603 million to $1,618 million"},{"label":"EPS","value":"$3.15 to $3.25"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e116385751d8e4e07f5141304ab9dde9d622f0e5","claim":"INTEGRA LIFESCIENCES HOLDINGS CORP reported full-year 2023 results: revenue $1,541.6 million, net income $67.7 million, EPS $0.84.","evidence_excerpt":"Total reported revenues for the full-year 2023 were $1,541.6 million, a decrease of 1.0%, from the prior year. Organic sales for the full-year 2023 were flat compared to 2022. Revenue increas ed 5.5% on an organic basis excluding Boston. The Company reported GAAP net income of $67.7 million, or $0.84 per diluted share, for the full-year 2023, compared to GAAP net income of $180.6 million, or $2.16 per diluted share in 2022. Adjusted EBITDA for the full-year 2023 was $369.7 million, a decrease of $41.6 million versus the prior year. Full year EBITDA margins were 24.0% a decrease of 240 basis points from the prior year. Adjusted net income for the full-year 2023 was $247.8 million, or $3.10 per diluted share, compared to $280.9 million, or $3.36 per diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752024000017/0000917520-24-000017-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"Revenue","value":"$1,541.6 million"},{"label":"Net income","value":"$67.7 million"},{"label":"EPS","value":"$0.84"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ea66bb368a4bc5535b2fbc0cdeed59349b613866","claim":"INTEGRA LIFESCIENCES HOLDINGS CORP reported fourth quarter 2023 results: revenue 397.0 million, net income $19.8 million, EPS $0.25.","evidence_excerpt":"Total reported revenues for the fourth quarter were 397.0 million, a decrease of 0.2% from the fourth quarter of 2022. Fourth quarter organic revenues were down 1.2% compared to the prior year. Revenue increased 3.6% on an organic basis excluding Boston. The Company reported GAAP net income of $19.8 million, or $0.25 per diluted share, in the fourth quarter of 2023, compared to GAAP net income of $52.9 million, or $0.63 per diluted share, in the prior year. Adjusted EBITDA for the fourth quarter of 2023 was $100.5 million, compared to $109.7 million in the fourth quarter of the prior year. As a percentage of revenue, adjusted EBITDA was 25.3%, a decrease of 230 basis points from the prior year period. Adjusted net income for the fourth quarter of 2023 was $69.1 million, or $0.89 per diluted share, compared to adjusted net income of $78.8 million, or $0.94 per diluted share, in the fourth quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752024000017/0000917520-24-000017-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter 2023"},{"label":"Revenue","value":"397.0 million"},{"label":"Net income","value":"$19.8 million"},{"label":"EPS","value":"$0.25"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}